MIMEDX to Host Virtual Investor Day on December 7, 2021
Marietta, Ga. – MiMedx Group, Inc. (Nasdaq: MDXG) announced a virtual Investor Day on December 7, 2021, at 9:00 a.m. ET. The event will showcase the Company’s late-stage pipeline in musculoskeletal conditions and its advanced wound care business. Further registration details will be shared soon. A live webcast is accessible via the Company’s Investors section at www.mimedx.com, with a replay available post-event. MiMedx specializes in amniotic tissue for regenerative medicine, addressing severe non-healing wounds and musculoskeletal pain.
- None.
- None.
MARIETTA, Ga., Oct. 14, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will host a virtual Investor Day on Tuesday, December 7, 2021 beginning at 9:00 a.m. ET. The event will focus on the Company’s musculoskeletal late-stage pipeline and advanced wound care business. Further details regarding registration, presenters and format will follow.
A live webcast will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com at the time of the event. A replay of the webcast will be available on the Company’s website following the conclusion of the event.
About MIMEDX
MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
Contact:
Jack Howarth
Investor Relations
404-360-5681
jhowarth@mimedx.com
Contact:
Hilary Dixon
Corporate & Strategic Communications
404-323-4779
hdixon@mimedx.com
FAQ
What is the date and time of MiMedx's Investor Day 2021?
How can I access the MiMedx Investor Day event?
What will be discussed during the MiMedx Investor Day?
Where can I find the replay of the MiMedx Investor Day?
What sectors does MiMedx Group operate in?
